Rôle de la MGMT et implications cliniques dans les tumeurs cérébrales [Role of MGMT and clinical applications in brain tumours]

Détails

ID Serval
serval:BIB_72D7781ECE93
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Rôle de la MGMT et implications cliniques dans les tumeurs cérébrales [Role of MGMT and clinical applications in brain tumours]
Périodique
Bulletin du cancer
Auteur(s)
Paus C., Murat A., Stupp R., Regli L., Hegi M.
ISSN
1769-6917[electronic]
Statut éditorial
Publié
Date de publication
2007
Volume
94
Numéro
9
Pages
769-73
Langue
français
Notes
Publication types: English Abstract ; Journal Article ; Review - Publication Status: ppublish
Résumé
Glioblastoma multiforme is the most common and most malignant primary brain tumour with a dismal prognosis. The advent of new chemotherapies with alkylating agents crossing the blood-brain barrier, like temozolomide, have permitted to notably ameliorate the survival of a subgroup of patients. Improved outcome was associated with epigenetic silencing of the MGMT (O6-methylguanin methyltransferase) gene by promotor methylation, thereby blocking its repair capability, thus rendering the alkylating agents more effective. This particularity can be tested by methylation specific PCR on resected tumour tissue, best on fresh frozen biopsies, and allows identification of patients more susceptible to respond favourably to the treatment.
Mots-clé
Antineoplastic Agents, Alkylating, Brain Neoplasms, DNA Methylation, DNA Modification Methylases, DNA Repair Enzymes, Drug Resistance, Neoplasm, Gene Silencing, Gene Targeting, Glioblastoma, Humans, Neoplasm Proteins, Promoter Regions, Genetic, Treatment Outcome, Tumor Suppressor Proteins
Pubmed
Web of science
Création de la notice
30/07/2008 10:39
Dernière modification de la notice
03/03/2018 18:18
Données d'usage